TP53 and myeloid neoplasm: Acute myeloid leukemia (AML) harboring TP53 mutations, which is now classified as a distinct AML subtype according to the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias [2], presents a redoubtable clinical challenge as it is associated with an adverse prognosis [3,4,5].